Results 171 to 180 of about 1,977,916 (307)

Impact of Complex Genetic and Drug-Drug Interactions on Tamoxifen Metabolism and Efficacy. [PDF]

J Pers Med
Saad I, Bentayebi K, Ettoury S, Zarrik O, Bourais I, Boutayeb S, Samer C, Daali Y, Eljaoudi R, Louati S.   +9 more
europepmc   +1 more source

Importance of drug-drug interactions in drug safety [PDF]

, 2004
Rätz Bravo, Alexandra Elisabeth
core   +1 more source

LDAcoop: Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro

Molecular Oncology, EarlyView.
Limiting dilution assays (LDAs) quantify clonogenic growth by seeding serial dilutions of cells and scoring wells for colony formation. The fraction of negative wells is plotted against cells seeded and analyzed using the non‐linear modeling of LDAcoop.
Nikko Brix, Daniel Samaga, Katharina Gehr, Benedek Dankó, Mohamed Schumann, Guido Drexler, Ahmed Alnatsha, Georg Beyer, Ujjwal Mahajan, Martin Selmansberger, Julia Mayerle, Claus Belka, Horst Zitzelsberger, Kirsten Lauber   +13 more
wiley   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Small RNA or oligonucleotide drugs and challenges in evaluating drug-drug interactions. [PDF]

Front Pharmacol
Cronin JM, Yu AM.
europepmc   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

CYP2C8-Mediated Drug-Drug Interactions and the Factors Influencing the Interaction Magnitude. [PDF]

Drug Des Devel Ther
Zhu LL, Yu LY, Wang YH, Zhou Q.
europepmc   +1 more source

BiGraph‐DTA: Predicting drug–target interactions of hepatoprotective agents with graph convolutional networks [PDF]

Arief Sartono, Bambang Riyanto Trilaksono, Sophi Damayanti, Anto Satriyo Nugroho, Firdayani Firdayani, Arief Sartono, Bambang Riyanto Trilaksono, Sophi Damayanti, Anto Satriyo Nugroho, Firdayani Firdayani   +9 more
openalex   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Evaluation of in vitro drug-drug interactions of ivermectin and antimalarial compounds. [PDF]

Malar J
Tipthara P, Kullasakboonsri R, Kobylinski KC, Tarning J.   +3 more
europepmc   +1 more source